Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 15, 2017
Pharmacy Choice - Pharmaceutical News - FDA Approves a Trackable `Digital Pill` That Delivers Schizophrenia Medication [All Iraq News Agency (AIN)] - December 15, 2017

Pharmacy News Article

 11/16/17 - FDA Approves a Trackable `Digital Pill` That Delivers Schizophrenia Medication [All Iraq News Agency (AIN)]

The FDA has announced its first ever approval of a pill with an embedded sensor that digitally tracks if patients have ingested it, ushering the US into a new era of smart pharmaceuticals and medical surveillance.

The treatment, called Abilify MyCite, is essentially a clever delivery system for the antipsychotic aripiprazole, used to treat schizophrenia and bipolar disorder. And now, for the first time, doctors prescribing the drug will know first-hand if their patients are actually taking it.

"Being able to track ingestion of medications prescribed for mental illness may be useful for some patients," says the FDA`s director of psychiatric drugs evaluation, Mitchell Mathis.

"The FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers."

Abilify MyCite`s tracking system is centred around a tiny ingestible sensor about the size of a grain of sand, called an Ingestible Event Marker (IEM), made from safe levels of copper, magnesium and silicon.

Once the pill and the IEM inside it are swallowed, stomach acid activates the sensor, sending an electrical signal to a wearable patch worn on the patient`s chest. The patch records the date and time the pill was ingested, and relays this information to a smartphone app.

Users of the app including the patient, but also any authorised doctors or family members can then check in on the patient`s ingestion data, keeping direct tabs on the timely swallowing of oral medication in private like never before.

In other words, that old hide-the-pill-under-your-tongue trick will not work here.

The smart pill`s manufacturers Otsuka (which makes Abilify) and Proteus (the IEM developer) bill their innovation as "the first digital medicine system", which they say will make it easier for caregivers to objectively monitor patients` adherence to medication regimens.

While there`s no research as yet to indicate the ingestion tracking system actually improves patients` compliance in taking their meds, the companies are hopeful that it might do just that which, in the case of schizophrenia, could potentially help mitigate the symptoms of the 1.1 percent of Americans with the illness.

But some experts are concerned about the psychological ramifications of a drug that essentially acts as a tattletale if you don`t take it the right way, especially considering the target market for aripiprazole.

"Many [schizophrenia] patients don`t take meds because they don`t like side effects, or don`t think they have an illness, or because they become paranoid about the doctor or the doctor`s intentions," psychiatrist Paul Appelbaum from Columbia University told The New York Times.

"A system that will monitor their behaviour and send signals out of their body and notify their doctor? You would think that, whether in psychiatry or general medicine, drugs for almost any other condition would be a better place to start than a drug for schizophrenia."

Those concerns were shared by fellow Columbia University psychiatrist Jeffrey Lieberman, who likened Abilify MyCite to "a biomedical Big Brother", noting the "irony in it being given to people with mental disorders than can include delusions".

Yet, the ultimate impact of an embedded drug monitoring system like this goes well beyond the treatment of just schizophrenia and mental illness.

Non-adherence to recommended medication taking patterns in the US has been estimated to cost more than US$105 billion annually, so there are important economic factors behind the FDA`s approval.

But while Abilify MyCite may be the first of these kinds of drugs, it almost definitely won`t be the last, with reports the FDA is anticipating a coming wave of such self-monitoring medications.

If so, we could soon be looking at a new level of data-driven surveillance in the healthcare sector, bringing up all kinds of questions and concerns about ethics, privacy, personal rights, and whether this kind of ingestion tracking can truly be safeguarded in the interests of the patient.

"We`ve seen time and time again that stuff that`s being transmitted ends up in the hands of people it shouldn`t," pharmaceutical policy researcher Walid Gellad from the University of Pittsburgh told NPR.

"There are real concerns about data security."

Before we have all the answers to those questions, Abilify MyCite is expected to hit the market sometime next year, and for better or worse, the seeds of snitch medication will have been planted.



(c) 2017 AIN. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Dec 15: Mobile Applications for Pharmacists: Tools That Help Pharmacies be Successful
Dec 17: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Dec 18: Management of Alcohol Use Disorders
Dec 19: Medication Adherence: To Take or Not to Take…That is the Problem
Dec 20: Type II Diabetes: Case Studies and Management Options
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415